What happened with ACIU today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
AC Immune SA develops experimental treatments and diagnostics targeting abnormally folded proteins associated with Alzheimer’s, Parkinson’s and other neurodegenerative diseases. It has no products approved for sale and earns no revenue from drug or diagnostic sales.
Pharmaceutical partners pay AC Immune for rights to its candidates and for development work, with further payments tied to specified development or commercial milestones. Takeda is currently its main source of contract revenue. Their agreement covers Alzheimer’s immunotherapies including ACI-24.060, which is intended to stimulate patients to produce antibodies against a disease-related protein. AC Immune must complete the ABATE trial; if Takeda exercises its licensing option, Takeda would fund further development and handle regulatory activities and commercialization. Lilly and Janssen also hold rights to other treatment programs.
Revenue varies with new agreements and milestone achievements rather than recurring product sales. AC Immune relies heavily on partners to advance licensed candidates, and they can terminate their agreements. Candidates cannot be marketed before regulatory approval, and sales royalties would begin only if a product gains approval and is successfully commercialized.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
AC Immune depends on clinical success and partner payments; also watch Eisai, absent from this list, whose Leqembi, developed with Biogen, is an important competing Alzheimer’s treatment.
Takeda is a source of payments for AC Immune’s amyloid-beta immunotherapies and would fund further development and worldwide commercialization after exercising its licensing option and meeting closing conditions. Watch its decision on ACI-24.060: exercising the option would bring AC Immune an exercise fee, with milestones and sales royalties potentially to follow.
Johnson & Johnson’s Janssen pays AC Immune for progress in its licensed anti-tau immunotherapies and takes responsibility for clinical development, manufacturing and commercialization from Phase 2b onward. Watch the ACI-35.030 ReTain trial: rapid prescreening generated a CHF 24.6 million milestone that AC Immune recognized as revenue in 2024.
Eli Lilly funds development of AC Immune’s licensed tau-targeting small-molecule drugs, offering potential milestones and sales royalties, but its marketed Alzheimer’s medicine Kisunla also competes with AC Immune’s prospective treatments. Watch progress toward dosing the first patient in a US or EU Phase 2 study of the licensed program, which is tied to a CHF 60 million milestone.
Biogen’s Leqembi, developed with Eisai, already treats Alzheimer’s disease by targeting amyloid and competes with AC Immune’s prospective amyloid-beta immunotherapies. Its safety and efficacy provide a concrete comparison for AC Immune’s ACI-24.060 program.
Acumen Pharmaceuticals’ sabirnetug targets small clusters of amyloid-beta, called oligomers, and competes with AC Immune’s immunotherapy program for Alzheimer’s treatments that address the disease itself. Watch sabirnetug’s safety and efficacy rather than sales: Acumen had no approved products or product-sales revenue through 2025.
ProMIS Neurosciences competes with AC Immune by developing treatments aimed at harmful protein forms rather than normal ones, including amyloid-beta and tau. Watch its Alzheimer’s candidate PMN310’s safety and efficacy, the concrete test of this overlapping approach; ProMIS plans to license marketing and sales to partners if candidates succeed.
Prothena competes with AC Immune for Alzheimer’s and other neurodegenerative treatment markets by developing drugs aimed at disease-causing proteins. Its Alzheimer’s program BMS-986446 with Bristol Myers Squibb is a concrete clinical program to watch for competing progress.
Lantheus links AC Immune’s licensing returns to development of compounds that make tau visible on PET scans, rather than to treatment sales. Lantheus sells diagnostic products mainly to hospitals and imaging centers; watch LNTH-2620, whose composition and use patents it co-owns with AC Immune.
Alector’s Alzheimer’s antibodies and tau-targeting research compete for the patients AC Immune’s amyloid-beta and tau programs aim to treat. Watch nivisnebart’s Phase 2 early-Alzheimer’s trial with GSK, while Alector’s brain-penetrating amyloid-beta antibody and tau programs remain preclinical or in research.
Denali Therapeutics competes with AC Immune’s Alzheimer’s programs by developing amyloid-beta and tau treatments designed to reach the brain. Watch whether its technology for carrying antibodies and gene-targeting molecules across the blood-brain barrier delivers better plaque clearance and broad brain distribution; the supplied distribution findings are preclinical, not patient results.
Anavex Life Sciences develops clinical-stage Alzheimer’s and Parkinson’s treatments that compete for patients in AC Immune’s neurodegenerative disease markets. Watch ANAVEX2-73’s Alzheimer’s results by genetic subgroup: Anavex says its genomic analysis may help identify patients more likely to respond.
Annovis Bio’s buntanetap competes with AC Immune’s prospective Alzheimer’s treatments through a different approach: it is designed to reduce production of several toxic proteins that aggregate. Watch whether buntanetap’s results support that claim; Annovis had no product-sales revenue through 2025.
Cognition Therapeutics’ small-molecule drugs, including zervimesine, compete for the Alzheimer’s treatment market AC Immune’s pipeline targets. Watch zervimesine’s clinical progress rather than current sales: Cognition does not expect product-sales revenue until a candidate completes development and receives approval.
Biogen Inc. earningsBIIB
Biogen’s report will show how its Alzheimer’s drug Leqembi is being used, a check on the commercial competition AC Immune’s prospective ACI-24.060 could face from an amyloid-targeting treatment.
Look for whether Leqembi use and related revenue are growing. Rising use would show more patients are receiving an amyloid-targeting treatment, making the commercial competition for AC Immune’s prospective therapy more established; flat use would mean that competition has not yet translated into broader treatment demand, but would not tell us whether ACI-24.060 works.
Takeda Pharmaceutical Company Limited earningsTAK
Takeda’s report may show progress in the amyloid-immunotherapy program that includes ACI-24.060; if Takeda exercises its option, it would take on later development funding and commercialization.
Look for disclosed program progress or an option decision. Progress to exercising the option could bring AC Immune an exercise fee, with Takeda funding later clinical development after licensing; without that progress, AC Immune remains responsible for completing ABATE and the funding and development handoff has not occurred.
Eli Lilly & Co. earningsLLY
Lilly’s report may show whether its licensed tau small-molecule program is nearing a Phase 2 first-patient dose, a milestone that could bring AC Immune CHF 60 million.
Look for Lilly’s disclosure of progress toward Phase 2 and whether dosing the first patient is near. Reaching that point could trigger a CHF 60 million milestone payment to AC Immune; if the program has not advanced, that potential revenue remains out of reach and the work still depends on Lilly’s pace.
AC Immune SA earningsThis company
AC Immune has no approved products, so this report shows whether collaboration revenue is helping fund the research that could eventually bring in product sales.
Read contract revenue alongside cash used in operating activities. More recognized collaboration revenue with slower cash use would show partner work is helping support research; little revenue while cash use stays high would mean AC Immune still relies on its liquidity, future milestone payments or financing to keep programs moving.
